ArticleRMD open2024
Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.
Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Increased severity and relapse rate in adult anti-nuclear matrix protein 2 antibody positive myositis patients with distal limb weakness: a retrospective study in China.Frontiers in medicine · 2026Article
- Perioperative management of anti-TIF1-γ dermatomyositis in a patient with breast cancer: a case report.Frontiers in medicine · 2026Article
- Anti-MDA5-like ulcerated Gottron's papules in anti-NXP2 dermatomyositis.Clinical rheumatology · 2026Article
- Review
- An update on autoantibodies in the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2025Review
- Calcinosis in dermatomyositis.Current opinion in rheumatology · 2024Review
- Gastrointestinal Vasculitis in Adult Patient With Dermatomyositis Presenting as Hematemesis.ACG case reports journal · 2024Article
- Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature.Frontiers in pediatrics · 2024Article
- Juvenile dermatomyositis complications: navigating gastrointestinal perforations and treatment challenges, a case report.Frontiers in pediatrics · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGastrointestinal (GI) involvements were scarcely reported in adult anti-nuclear matrix protein 2 (NXP2) dermatomyositis (NXP2
methodsWe retrospectively collected the data of the cohort of NXP2
resultsA total of 56 patients with adult NXP2
conclusionsGI involvement is a unique complication in patients with adult NXP2+DM. Timely recognition and targeted therapy may turn out to be lifesaving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.